Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Intravenous and intra-arterial thrombolysis for acute ischemic stroke following interventional cardiac procedures: A systematic review and narrative synthesis

Acute ischemic stroke is a rare but potentially devastating complication of interventional cardiac procedures, and evidence on thrombolysis remains limited. To systematically review intravenous and intra-arterial thrombolysis (IVT and IAT) for ischemic stroke during or after cardiac procedures, focusing on n...

L. D'Anna, G. Prandin, S. Abu-Rumeileh et al. · 0 citations
Open access Oct 2026

Beyond seizure control: Non-seizure-related outcomes in focal-onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS study.

OBJECTIVE Cenobamate is approved for treatment of focal seizures in adults, but evidence on non-seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal-onsEt SeizureS (BLESS) study evaluated patient- and clinician-reported outcomes for up to 52 weeks of cenobamate trea...

Simona Lattanzi, G. d'Orsi, M. T. Di Claudio et al. · 0 citations
Open access Sep 2026

Reduced volume of neuromodulatory brainstem nuclei is associated with early hallucination-related vulnerability in Parkinson’s disease

Abstract Early hallucination-related phenomena, including minor visual hallucinations (mVHs), are clinically relevant features of Parkinson’s disease (PD), but their neuroanatomical substrates remain unclear. Brainstem nuclei supporting sensory gating, together with cholinergic and noradrenergic dysregulation, are prop...

Gabriella Monopoli, Federica Tomaiuolo, C. Sestieri et al. · 0 citations
Open access Aug 2026

Predictors of subsequent relapse-independent progression after high-efficacy therapy in relapsing multiple sclerosis

Background and objectives Progression independent of relapse activity (PIRA) is increasingly recognized as a major driver of disability accumulation in multiple sclerosis (MS). However, the factors associated with PIRA occurring after initiation of high-efficacy therapies (HETs) remain poorly investigated. We aimed to...

M. Foschi, A. Surcinelli, I. Panzera et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.